Literature DB >> 15471560

Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers.

Toshio Takada1, Yukiko Yagi, Takao Maekita, Masayoshi Imura, Shunsuke Nakagawa, Sai-Wah Tsao, Kazuaki Miyamoto, Osamu Yoshino, Toshiharu Yasugi, Yuji Taketani, Toshikazu Ushijima.   

Abstract

The SFRP1 gene on chromosome 8p11.2 encodes a Wnt signaling antagonist, and was recently demonstrated to be a new tumor suppressor that is inactivated by promoter methylation in human colon cancers. Here, we analyzed promoter methylation of the SFRP1 gene in human ovarian cancers, in which loss of heterozygosity in 8p is frequently observed and involvement of the Wnt signaling pathway has been suggested. Methylation-specific PCR (MSP) analysis showed that four of 13 ovarian cancer cell lines and two of 17 primary ovarian cancers had methylated SFRP1, while an immortalized ovarian epithelial cell line, HOSE, and seven ovarian endometrial cyst samples did not. In the four ovarian cancer cell lines with the methylation, SFRP1 was not expressed at all as determined by quantitative RT-PCR analysis. A cell line with SFRP1 methylation, MCAS, was treated with a demethylating agent, 5-aza-2'-deoxycytidine, and demethylation of the promoter and re-expression of SFRP1 were observed. These results show that SFRP1 is inactivated by promoter methylation in human ovarian cancers, as well as colon cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471560     DOI: 10.1111/j.1349-7006.2004.tb03255.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  35 in total

1.  Hypermethylation and aberrant expression of secreted frizzled-related protein genes in pancreatic cancer.

Authors:  Xian-Min Bu; Cheng-Hai Zhao; Ning Zhang; Feng Gao; Shuai Lin; Xian-Wei Dai
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

2.  Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

Authors:  Simon J Cooper; Christina A von Roemeling; Kylie H Kang; Laura A Marlow; Stefan K Grebe; Michael E Menefee; Han W Tun; Gerardo Colon-Otero; Edith A Perez; John A Copland
Journal:  Mol Cancer Ther       Date:  2012-07-23       Impact factor: 6.261

Review 3.  Can we safely target the WNT pathway?

Authors:  Michael Kahn
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

4.  Application of multiplex methylated-specific PCR with capillary electrophoresis to explore prognostic value of TSGs hypermethylation for hepatocellular carcinoma.

Authors:  Yuan Huang; Ling Wei; Ai-Min Sun; Bo Li; Cheng-Jun Sun; Wei-Bo Liang; Qiu-Ying Liu; Xiao-Qin Yu; Jing-Yang He; Yang Qin
Journal:  J Clin Lab Anal       Date:  2018-03-07       Impact factor: 2.352

5.  Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Ramez N Eskander; Shamshad Ali; Thanh Dellinger; Heather A Lankes; Leslie M Randall; Nilsa C Ramirez; Bradley J Monk; Joan L Walker; Eric Eisenhauer; Bang H Hoang
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

Review 6.  Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression.

Authors:  Tura C Camilli; Ashani T Weeraratna
Journal:  Biochem Pharmacol       Date:  2010-03-06       Impact factor: 5.858

Review 7.  Wnt signaling in ovarian tumorigenesis.

Authors:  T A Gatcliffe; B J Monk; K Planutis; R F Holcombe
Journal:  Int J Gynecol Cancer       Date:  2007-11-06       Impact factor: 3.437

8.  Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia.

Authors:  Kyung-Ok Uhm; Eun Soo Lee; Yun Mi Lee; Jeong Seon Park; Seok Jin Kim; Byung Soo Kim; Hyeon Soo Kim; Sun-Hwa Park
Journal:  J Korean Med Sci       Date:  2009-06-18       Impact factor: 2.153

9.  WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth.

Authors:  Yutaka Matsuda; Thomas Schlange; Edward J Oakeley; Anne Boulay; Nancy E Hynes
Journal:  Breast Cancer Res       Date:  2009-05-27       Impact factor: 6.466

10.  Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MT1-MMP in gastric cancer.

Authors:  Chenghai Zhao; Xianmin Bu; Ning Zhang; Wei Wang
Journal:  BMC Cancer       Date:  2009-07-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.